Mako Surgical's Market Penetration is Key Print E-mail
By Brian Wilson, Contributor   
Tuesday, 21 August 2012 04:06
icon_closerlookShares of the

Error. Page cannot be displayed. Please contact your service provider for more details. (6)

medical device company Mako Surgical Corp. (NASDAQ: MAKO) have seen a steady recovery after the company released quarterly results (for Q2 2012) in early August. Although recent gains have been significant, they are still nothing compared to the drop we saw on July 10th where the company initially hinted that the second quarter was not going to produce the results that investors were hoping for.
Read more...
 
Gilead Sciences Showing Strength Print E-mail
By Brian Wilson, Contributor   
Monday, 20 August 2012 02:32
icon_newsnotesGilead Sciences (NASDAQ: GILD) has been breaking new highs on the stellar prospects of their latest HIV pill, Truvada, which received FDA approval as an AIDS prevention drug approximately one month ago.
Read more...
 
Think Long Term and Win Big with Small Biotechs: Hugh Cleland Print E-mail
By George S. Mack of The Life Sciences Report   
Wednesday, 15 August 2012 07:49
hugh_clelandBluMont Capital Portfolio Manager Hugh Cleland has taken a venture capital and private equity approach to investing in public companies, some of which have penny-stock market caps in the $5–15 million range.
Read more...
 
CEO of GeoVax Discusses His Firm's Leading HIV Therapeutic Vaccine Candidate Print E-mail
By Staff and Wire Reports   
Tuesday, 14 August 2012 09:05
icon_ceoexclusiveGeoVax Labs Inc (OTCBB:GOVX) is an emerging biotechnology company engaged in the development of human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents.
Read more...
 
Why the Exelixis Offering Makes Sense Print E-mail
By Brian Wilson, Contributor   
Monday, 13 August 2012 09:23
icon_newsnotesExelixis (NASDAQ: EXEL) is the clinical stage pharmaceutical company whose shares we’ve been watching since ASCO 2012.
Read more...
 
Talon Therapeutics Looks Undervalued Following FDA Approval Print E-mail
By Brian Wilson, Contributor   
Friday, 10 August 2012 04:03
icon_fdaapprovalShareholders of Talon Therapeutics (OTC: TLON) saw a pleasant surprise on August 9th when the FDA approved the company’s flagship product, Marqibo, three days earlier than expected.
Read more...
 
Amarin's Next Catalysts Could Push Shares Higher Print E-mail
By Brian Wilson, Contributor   
Thursday, 09 August 2012 05:15
icon_MarketCatalystAfter a lengthy period of market speculation over the potential acquisition of Amarin Corporation (NASDAQ: AMRN), which drove shares as high as $15.96, the market sold the stock quite heavily following FDA approval for its flagship product AMR101 (now known as Vascepa) for the treatment of high triglycerides. Vascepa is coming into the market as the only prescription fish oil pill since GlaxoSmithKline’s (NYSE: GSK) Lovaza, which brings GSK over $1 billion a year in sales revenue.
Read more...
 
Vanda Pharmaceuticals: More Than Enough Cash on Hand to Buy Themselves Print E-mail
By Scott Matusow, Contributor   
Wednesday, 08 August 2012 01:25
icon_bottombouncer I've came across an interesting small cap biopharma I feel investors should take a hard look at. The company has more cash on hand than its current market cap, with no debt, and a substantial partnership with a large pharma:
Read more...
 
Q&A: MediciNova CEO, Dr. Yuichi Iwaki Print E-mail
By M.E.Garza   
Tuesday, 07 August 2012 02:55
icon_ceoexclusiveDr. Yuichi Iwaki, President and CEO of Nasdaq listed small-cap MediciNova, Inc. (NASDAQ:MNOV) took the time to answer our questions about his firm's pipeline, upcoming milestones and recent clinical trial results.
Read more...
 
Breaking News Indicates PSTI's Cell Therapy for Bone Marrow Could Be A Blockbuster Print E-mail
By Ray Dirks of Ray Dirks Research   
Monday, 06 August 2012 01:46
icon_alert_newsThe world watched in May as Pluristem (NASDAQ:PSTI) miraculously healed a young girl dying from bone marrow that was so diseased it had lost most of its blood cells. No medical intervention had worked. Yet after two intramuscular injections of PLX cells, within weeks, she left the hospital and
has been well ever since. It might be easy to believe this was a fluke, but the company has just done it again.
Read more...
 
<< Start < Prev 51 52 53 54 55 Next > End >>

Page 52 of 55
BMR:1